Outcomes of patients with melioidosis treated with meropenem

Antimicrob Agents Chemother. 2004 May;48(5):1763-5. doi: 10.1128/AAC.48.5.1763-1765.2004.


Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >/=14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Ceftazidime / therapeutic use
  • Cephalosporins / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Melioidosis / drug therapy*
  • Melioidosis / mortality
  • Meropenem
  • Middle Aged
  • Prospective Studies
  • Sepsis / complications
  • Thienamycins / adverse effects
  • Thienamycins / therapeutic use*
  • Treatment Outcome


  • Cephalosporins
  • Thienamycins
  • Ceftazidime
  • Meropenem